Innovative Product PipelineTC Biopharm's focus on gamma-delta T cell technology positions it at the forefront of innovative cancer treatments, offering potential long-term growth through successful product development and commercialization.

Strategic PartnershipsStrategic partnerships with larger pharmaceutical firms provide TC Biopharm with financial support and market access, enhancing its ability to bring therapies to market and generate sustainable revenue.

Equity ImprovementImprovement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future financial stability and growth.

Bears Say

Declining RevenuesA significant decline in revenue indicates challenges in product commercialization and market penetration, posing risks to long-term financial viability and growth prospects.

Negative Cash FlowPersistent negative cash flow from operations suggests difficulties in sustaining business activities without external financing, impacting long-term operational sustainability.

High Debt LevelsHigh debt levels can strain financial resources, limiting flexibility and increasing risk, which could hinder the company's ability to invest in growth opportunities and weather economic downturns.

TC Biopharm (Holdings) News

TC BioPharm Appoints Interim Liquidators Amid Deregistration Plans

TC Biopharm (Holdings) ( ($TCBPY) ) has issued an announcement. On November 10, 2025, TC BioPharm (Holdings) plc...

4M ago

TC BioPharm Limited Enters Administration Amid Asset Sale Exploration

TC Biopharm (Holdings) ( ($TCBPY) ) has shared an announcement. On October 2, 2025, TC BioPharm Limited, a...

5M ago

TC BioPharm Approves Key Resolutions at 2025 Annual Meeting

TC Biopharm (Holdings) ( ($TCBPY) ) has provided an update. On August 29, 2025, TC BioPharm (Holdings) plc...

6M ago

TC BioPharm Announces Annual General Meeting for August 2025

TC Biopharm (Holdings) ( ($TCBPY) ) has shared an update. On August 5, 2025, TC BioPharm (Holdings) plc...

7M ago

TC Biopharm Adjourns Shareholder Meeting Indefinitely

TC Biopharm (Holdings) ( ($TCBPY) ) has issued an update. On May 22, 2025, TC Biopharm (Holdings) PLC...

9M ago

TC BioPharm Announces General Meeting to Discuss Key Resolutions

TC Biopharm (Holdings) ( ($TCBPY) ) has shared an update. On May 6, 2025, TC BioPharm (Holdings) PLC...

10M ago

TCBPY FAQ

What was TC Biopharm (Holdings)’s price range in the past 12 months?

TC Biopharm (Holdings) lowest stock price was $0.03 and its highest was $2.25 in the past 12 months.

What is TC Biopharm (Holdings)’s market cap?

TC Biopharm (Holdings)’s market cap is $32.52K.

When is TC Biopharm (Holdings)’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were TC Biopharm (Holdings)’s earnings last quarter?

Currently, no data Available

Is TC Biopharm (Holdings) overvalued?

According to Wall Street analysts TC Biopharm (Holdings)’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does TC Biopharm (Holdings) pay dividends?

TC Biopharm (Holdings) does not currently pay dividends.

What is TC Biopharm (Holdings)’s EPS estimate?

TC Biopharm (Holdings)’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TC Biopharm (Holdings) have?

TC Biopharm (Holdings) has 2,103,054 shares outstanding.

What happened to TC Biopharm (Holdings)’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of TC Biopharm (Holdings)?

Currently, no hedge funds are holding shares in TCBPY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

TC Biopharm (Holdings)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.